A controlled study of vigabatrin and visual abnormalities

British Journal of Ophthalmology

Volumn 84, Issue 5, 2000, Pages 499-505

  Manuchehri, Kaykhosrov ^a   Goodman, Sarah ^a   Siviter, Lynn ^a   Nightingale, Simon ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VIGABATRIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; EPILEPSY; FEMALE; HUMAN; MALE; MULTIINFARCT DEMENTIA; OPHTHALMOLOGY; PERIMETRY; PRIORITY JOURNAL; SCREENING TEST; VISION; VISUAL ACUITY; VISUAL DISORDER; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT; VITREOUS BODY DETACHMENT;

ADULT; AGED; ANTICONVULSANTS; CASE-CONTROL STUDIES; COLOR VISION DEFECTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PILOT PROJECTS; VIGABATRIN; VISION DISORDERS; VISUAL ACUITY; VISUAL FIELDS;

EID: 1642618108     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.84.5.499     Document Type: Article

References (13)

1. Wilson EA, Brodie MJ Treiman DM, eds. Modern management of epilepsy. London: Baillière-Tindell, 1996:723-48.
2. Ruether K, Pung T, Kellner U, et al. Electrophysiologic evaluation of a patient with peripheral visual field constriction associated with vigabatrin. Arch Ophthalmol 1998;116: 817-9.
3. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings, Neurology 1998;50:614-8.
4. Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double blind study. Lancet 1999;354:13-19.
5. Granstrom ML, Gaily E, Liukkomen E. Treatement of infantile spasms: results of a population-based study with vigabatrin as the first drug for spasms. Epilepsia 1999;40: 950-7.
6. Koo B. Vigabatrin in the treatment of infantile spasms. Pediatr Neurol 1999;20:106-10.
7. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin (with letters of correspondence appearing in BMJ 1997;314:1693-5). BMJ 1997;314:180-1.
8. Stephens MDB. Pharmacoepidemiology and Drug Safety 1997;6(S2):S18.
9. Zamponi N, Cardinali C. Open comparative long-term study if vigabatrin versus carbamazepine in newly diagnosed partial seizures in children. Arch Neurol 1999;56: 605-7.
10. Ylinen A, Salmenpera T, Mumford JP, et al. Long-term treatment with vigabatrin - 10 years of clinical experience. Seizure 1999;8:181-3.
11. Remler BF, Leigh RJ, Osorio I, et al. The characteristics and mechanisms of visual field disturbance associated with anticonvulsant therapy. Neurology 1990;40:791-6.
12. Daneshvar Hossein, Racette Lyne, Coupland SG, et al. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 106:1792-9.
13. Hoechst Marion Roussel pharmaceuticals. Data sheet for Sabril (vigabatrin). In: ABPI data sheet compendium 1999-2000. London: Datapharm Publications, 585-7.